Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
== Catabolism == Free 4-hydroxyproline is produced when collagen is broken down. Two possible pathways can be used to break it down: the hydroxyproline dehydrogenase (PRODH2) pathway results in the production of glycine, glyoxylate, glycolate, and oxalate, while the L-amino-acid oxidase pathway results in the production of pyrrole-2-carboxylate. This additional source of glycine is important in young livestock as mammal milk and plant-based feed is deficient in glycine.
== Etymology and usage == The accepted etymology identifies the first component of the word crowbar with the bird-name "crow", perhaps due to the crowbar's resemblance to the feet or beak of a crow. The first use of the term is dated back to c. 1400. It was also called simply a crow, or iron crow; William Shakespeare used the latter, as in Romeo and Juliet, Act 5, Scene 2: "Get me an iron crow and bring it straight unto my cell." In Daniel Defoe's 1719 novel Robinson Crusoe, the protagonist lacks a pickaxe so uses a crowbar instead: "As for the pickaxe, I made use of the iron crows, which were proper enough, though heavy."
=== Economics === In the United States, the price of for a vial of Humalog increased from US$35 in 2001 to $234 in 2015, or $10.06 and $29.36 per 100 units. In April 2019, Eli Lilly and Company announced they would produce a version selling for $137.35 per vial. The chief executive said that this was a contribution "to fix the problem of high out-of-pocket costs for Americans living with chronic conditions", but Patients for Affordable Drugs Now said it was just a public relations move, as "other countries pay $20 for a vial of insulin." In March 2023, Lilly announced a program capping their insulin prices at $35 per month.
In July 2025, Karoline Leavitt, the White House press secretary, stated that Trump had been diagnosed with chronic venous insufficiency. Trump's physician, Barbabella, wrote in a statement that bruising on Trump's right hand was attributed to his use of aspirin and frequent hand-shaking. It was later noted, however, that vascular tests confirmed that Trump in fact had swelling in his legs at the time of his diagnosis. Large bruises continued to appear on Trump's hands in August through December of 2025 and in 2026. On August 27, 2025, Vice President JD Vance stated that he was ready to become president; this led to speculation that Trump was seriously ill or dead. That day, he was seen leaving for golf, but a photo which Trump shared of himself on August 31 was determined to have potentially been taken on August 23, fueling further speculation of continuing health concerns. Increased discussion about his mental health occurred in August. A photograph of Trump leaving the White House on September 1 confirmed he was still alive, but led to more speculation about his health due to seeming changes in his appearance. Theories alleging that Trump suffered an ischemic stroke grew following the photos' release; Trump disputed suggestions that he suffered ill health, asserting that he "never felt better in [his] life" in an all-caps Truth Social post. On September 11, during a 9/11 commemoration at the Pentagon, the right side of Trump's face was said to droop down heavily, once again sparking concerns of a stroke.
== Further reading == Nakagawa, Allen S., LIMS implementation and management, Cambridge: Royal Society of Chemistry, 1994 Liscouski, Joe, Laboratory and Scientific Computing a Strategic Approach, John Wiley & Sons, New York, 1995 Gibbon, Gerst, "A Brief History of LIMS", Laboratory Automation and Information Management 1996, 32(1), 1-5 Myers, J. D.; Fox-Dobbs, C.; Laird, J.; Le, Dai; Reich, D.; Curtz, T., "Electronic laboratory notebooks for collaborative research", In Proceedings of the 5th International Workshops on Enabling Technologies: Infrastructure for Collaborative Enterprises (WET ICE'96) (WET-ICE '96) IEEE Computer Society, Washington, DC, USA, 1996, 47-. Paszko, Christine; Pugsley, Carol, "Considerations in selecting a laboratory information management system (LIMS)", American Laboratory, 2000, 32(18), 38-42 Paszko, Christine; Turner, Elizabeth; Hinton, Mary D., Laboratory Information Management Systems, Revised & Expanded.
Sources: en.wikipedia.org
Side effects of fentanyl analogues are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Illicitly used fentanyl analogues have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
== History == Willis Carrier, a mechanical engineer working for Buffalo Forge, is credited with inventing modern air conditioning in July 1902. In 1908, the Carrier Air Conditioner Company of America was created as a subsidiary of the Buffalo Forge Company, with Willis Carrier as its vice president. With the onset of World War I in late 1914, the Buffalo Forge Company, where Carrier had been employed for 12 years, decided to confine its activities entirely to manufacturing. The result was that in 1915, Carrier and six other engineers pooled $32,600 to form the Carrier Engineering Corporation. They purchased their first factory in 1920, in Newark, New Jersey. The very next year, Carrier solved a problem that had vexed the Islington Studios (owned by Famous Players–Lasky and then Paramount Pictures) in London -- thick fog coming into the stage set and suspending filming. A pressurized system that cooled air at a rate of "3,500,000 gallons per hour" and then delivered the dehumidified air at the temperature set by a thermostat, kept the interior air clear and camera-ready. In 1955, Carrier merged with Affiliated Gas Equipment, Inc., which owned the Bryant Heater Co., Day & Night Water Heater Co., and Payne Furnace & Supply Co. Carrier Corporation was acquired by United Technologies Corporation (UTC) in July 1979. Prior to the acquisition by UTC, Carrier Corporation was known as the Carrier Air Conditioning Company. International Comfort Products (ICP), headquartered in Lewisburg, Tennessee, was acquired by Carrier in 1999.
The water then traveled through the channels into sixteen fountains known as the "stairway of fountains", reserving the first water source for the Emperor. This incredible feat supplied the population of Machu Picchu, which varied between 300 and 1000 people when the emperor was present and also helped irrigate water to the farming steppes. The fountains and canal system were built so well that they would, after a few minor repairs, still work today. To go along with the Incas' advanced water supply system, an equally impressive drainage system was built as well. Machu Picchu contains nearly 130 outlets in the center that moved the water out of the city through walls and other structures. The agriculture terraces are a feature of the complicated drainage system; the steppes helped avoid erosion and were built on a slope to aim excess water into channels that ran alongside the stairways. These channels carried the runoff into the main drain, avoiding the main water supply. This carefully planned drainage system shows the Incas' concern and appreciation for clean water. Water engineer Ken Wright and his archaeological team found the emperor’s bathing room complete with a separate drain that carried off his used bath water so it would never re-enter Machu Picchu’s water supply.
Defence chiefs such as General Magnus Malan welcomed Botha's ascension, blaming previous battlefield reversals—namely, Operation Savannah—on Vorster's indecisive and "lackluster" leadership. Botha had generated a reputation for being a tenacious, uncompromising leader who would use South Africa's position of military strength to strike hard at its foreign enemies, particularly to retaliate against any form of armed provocation. He criticised the West and the US in particular as being unwilling to stand up to Soviet expansionism, and declared that if South Africa could no longer look to the "free world" for support, then it would prevent further communist inroads into the region itself. Within the first three months of his premiership, the length of military service for white conscripts was doubled, and construction began on several new SADF bases near the border. Although little in the tactical situation had changed when Botha assumed office, patrols now crossed into Angola much more frequently to intercept and destroy PLAN cadres along their known infiltration routes. PLAN was attempting to rebuild its forward operating bases after the loss of Chetequera. The insurgents had also been incensed by the Cassinga raid and publicly threatened retribution. "Strike a hard blow which Pretoria will not forget in a long time," deputy PLAN commander Solomon Huwala stated in a written directive to his staff. "We have been concentrating on attacking military targets and their forces, but they have decided to kill women and children.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.